与腾讯(00700.HK)合作的医疗初创Medopad B轮融资筹得2,500万美元
据《彭博通讯社》报道,与腾讯控股(00700.HK)合作的英国人工智能初创Medopad筹得2,500万美元作临床健康科技研究,而是次B轮融资是由Bayer领投。
Medopad位於英国,主要透过寻找及使用疾病的数码标示以协助治疗如阿兹海默症及糖尿病等,公司於去年与腾讯合作,开发可遥距监测柏金逊症患者的系统,而公司亦正努力在中国建立医疗人工智能实验室。公司同时亦有与包括强生在内的企业合作,透过可穿载装置监测病人情况并寻找最有效的治疗方案。 ~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.